Pharmacokinetics and Pharmacogenetics Studies of Rifampicin and Isoniazid in Ethiopian Tuberculosis Patients
No Thumbnail Available
Date
2024-04
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Addis Ababa University
Abstract
Introduction: Tuberculosis (TB) is an ancient disease of mankind and remains a major public
health problem despite tremendous efforts made to combat it. Globally, 10.6 million people fell
ill and 1.13 million died from TB in 2022. Short-course regimens of first-line anti-TB drugs can
cure about 90% of cases. However, the success of treatment appears to be on a declining trend
over time. Unfavorable TB treatment outcomes might result from altered plasma exposure to
antitubercular drugs. Rifampicin and isoniazid display wide between-patient pharmacokinetics
variability. Ethiopia is among the 20 high TB and TB-HIV burdens countries. Ethiopians display
significant genetic variation from other black African populations. Despite these facts, data on
the extent of exposure to rifampicin and isoniazid, as well as inter-patient variability in plasma
concentration, remains scarce among Ethiopian TB patients.
Objective: The study aimed to determine the plasma levels of rifampicin and isoniazid and
investigate the effect of genetic polymorphism and socio-demographic characteristics on the
pharmacokinetics of rifampicin and isoniazid in Ethiopian tuberculosis patients.
Methods: The study was conducted at the primary healthcare centers in Addis Ababa, Ethiopia.
A total of one hundred forty-six adult patients with newly diagnosed TB who had received 2
weeks of first-line anti-TB therapy were enrolled. Venous blood samples were drawn at three-
time points from the majority of the patients ranging from 1 to 7 h post-drug intake. Genotyping
of NAT2, SLCO1B1 (c.388A>G, c.521T>C), ABCB1 (c.3435C>T, c.4036A>G),
AADACc.841G>A, and CES-2 (c.269-965A>G) was done using TaqMan drug metabolism assay.
Rifampicin, isoniazid, and its metabolite concentration were determined using validated liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Population pharmacokinetic
(POPPK) modeling of rifampicin was done using NONMEM.
Results: The overall median isoniazid maximum plasma concentration (Cmax) was 4.73 μg/mL
and the area under the curve (AUC0-7h) was 11.21μg.h/mL. The majority of patients 94(64.4%)
had isoniazid Cmax within the recommended therapeutic range (3-6 μg/mL), while only 19 (13%)
had an isoniazid Cmax of below 3 μg/mL. The median rifampicin Cmax was 6.79μg/mL. Only 42
IV | P a g e
(29%) patients achieved the therapeutic efficacy threshold (> 8μg/mL). The median rifampicin
AUC0-7h was 17.055μg.h/mL. The frequency of slow, intermediate, and fast NAT2 acetylators
genotypes was 74.2%, 22.4%, and 3.3%, respectively. The overall concordance between NAT2
genotype and phenotype was 85%. The minor allele frequency for SLCO1B1*1B (c.388A>G),
SLCO1B1*5 (c.521T>C), ABCB1 c.3435C>T, ABCB1 c.4036A>G, AADAC c.841G>A and
CES-2 c.269-965A>G were 2.2%, 20.2%, 24.4%, 14.6%, 86.1% and 30.6%, respectively. NAT2
acetylator genotypes alone accounted for 26.1% and 40.6% of the variability in isoniazid Cmax
and AUC0-7h, respectively. ABCB1 c.4036A>G genotypes independently accounted for 7.4%,
and 6.1 % of the variability in rifampicin Cmax and AUC0-7h, respectively. A two-compartment
model coupled with a transit absorption model adequately fitted the rifampicin data. Subjects
with ABCB1 c.4036A>G GG genotype were estimated to have 41% lower intrinsic clearance of
rifampicin compared to subjects with ABCB1 c.4036A>G AA or AG genotypes. Similarly,
subjects with ABCB13435C TT genotype were estimated to have a 100% higher absorption rate
constant than those with ABCB1 3435C>T CC or CT genotypes.
Conclusion: There is high inter-patient variability in isoniazid and rifampicin exposure in
Ethiopian TB patients. The majority of the patients attained therapeutic plasma concentration of
isoniazid but not that of rifampicin. NAT2 acetylation genotypes, dose, and sex are strong
predictors of isoniazid exposure. Rifampicin exposure varied with sex, dose, ABCB1
c.4036A>G, and ADAC c.841G>A genotypes. The clinical significance of higher isoniazid and
lower rifampicin exposure in Ethiopian TB patients needs further investigation.
Description
Keywords
Rifampicin, isoniazid, pharmacokinetics, pharmacogenetics, Ethiopia, Tuberculosis